8-K: Allogene Therapeutics Advances CAR T Pipeline, Reports Q2 2024 Financials

Allogene Therapeutics announced the initiation of a pivotal Phase 2 trial for its lead candidate, cema-cel, and provided a financial update for the second quarter of 2024.

Summary

• Allogene Therapeutics reported its second quarter 2024 financial results and provided a business update.
• The company initiated the pivotal Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma (LBCL) in June 2024.
• Patient screening and enrollment for the ALPHA3 trial are proceeding as planned, with ten sites opened across the US.
• Enrollment for the ALPHA3 trial is expected to be completed in the first half of 2026, with a potential BLA submission in 2027.
• An IND application for ALLO-329 in autoimmune disease is on track for Q1 2025, with proof-of-concept data expected by the end of 2025.
• A Phase 1 data update for ALLO-316 in renal cell carcinoma (RCC) is planned for the end of 2024.
• Allogene ended Q2 2024 with $444.6 million in cash, cash equivalents, and investments.
• The company's cash runway is projected to extend into the second half of 2026.
• Research and development expenses for Q2 2024 were $50.4 million, including $5.3 million in non-cash stock-based compensation.
• General and administrative expenses for Q2 2024 were $16.1 million, including $8.2 million in non-cash stock-based compensation.
• The net loss for Q2 2024 was $66.4 million, or $0.35 per share, including $13.6 million in non-cash stock-based compensation and $5.0 million in non-cash impairment of long-lived asset expense.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024.
• GAAP operating expenses are expected to be approximately $300 million, including approximately $60 million in non-cash stock-based compensation.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and a solid cash position, although the company is still operating at a loss and has significant expenses. The initiation of the pivotal trial and the advancement of the pipeline are positive indicators.

Positives

• The initiation of the pivotal Phase 2 ALPHA3 trial is a significant milestone.
• The company is ahead of schedule with site activation for the ALPHA3 trial.
• The cash runway extends into the second half of 2026, providing financial stability.
• The company is making progress across its four core programs.
• The company is now manufacturing all of its CAR T investigational products in-house.
• The company received a $15 million award from the California Institute for Regenerative Medicine (CIRM) to support the TRAVERSE trial.

Negatives

• The company reported a net loss of $66.4 million for the second quarter of 2024.
• The company expects a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024.
• The company has significant operating expenses, with GAAP operating expenses expected to be approximately $300 million in 2024.

Risks

• Clinical trial outcomes may materially change as more patient data becomes available.
• There is no guarantee that Foresight will successfully develop an MRD assay for use as a companion diagnostic with cema-cel.
• The company may encounter difficulties enrolling patients in its clinical trials.
• The company may face challenges with manufacturing or optimizing manufacturing of its product candidates.
• The company's product candidates may cause undesirable side effects or have other properties that could halt their clinical development.
• The company may not be able to demonstrate the safety and efficacy of its product candidates in its clinical trials.

Future Outlook

The company expects its cash runway to fund operations into the second half of 2026 and anticipates a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024. GAAP operating expenses are expected to be approximately $300 million for 2024.

Management Comments

• The second quarter has been an excellent example of the power of momentum, particularly as we bring into the fold community cancer centers who are eager to be a part of our pivotal Phase 2 ALPHA3 trial and we are now manufacturing all of our CAR T investigational products in-house, said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
• Beyond the progress we've seen across our four core programs with cema-cel in blood cancers, ALLO-329 in autoimmune disease, and ALLO-316 in relapsed and refractory renal cell carcinoma, there is renewed energy from investigators, clinical trial sites, and top-tier investors as it becomes increasingly apparent that we have the potential to reshape the future of CAR T therapies.

Industry Context

Allogene is a clinical-stage biotechnology company focused on developing allogeneic CAR T cell therapies, which are 'off-the-shelf' treatments. This contrasts with autologous CAR T therapies, which are patient-specific. The company's progress in initiating a pivotal trial and advancing its pipeline positions it as a key player in the rapidly evolving field of cell therapy.

Comparison to Industry Standards

• Allogene's focus on allogeneic CAR T therapies aims to address the limitations of autologous CAR T therapies, such as manufacturing complexity and patient-specific production delays.
• Competitors in the CAR T space include companies like Gilead (Kite Pharma) and Novartis, which have approved autologous CAR T products. Allogene's approach seeks to offer a more scalable and readily available treatment option.
• The initiation of the ALPHA3 trial is a significant step, as it is the first pivotal trial to offer CAR T as part of 1L treatment consolidation, potentially setting a new standard in LBCL treatment.
• The company's in-house manufacturing capabilities are a strategic advantage, allowing for greater control over production and potentially reducing costs.
• The development of Dagger technology for autoimmune disease is innovative and could differentiate Allogene from competitors in this space.

Related Party Transactions

• Collaboration revenue of $22 thousand was reported from a related party.

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and cash runway, but concerned about the ongoing losses.
• Employees may be motivated by the company's progress and the potential to reshape the future of CAR T therapies.
• Patients may benefit from the development of new treatment options for cancer and autoimmune diseases.
• Investors may be interested in the company's innovative technology and potential for growth.

Next Steps

• Continue patient screening and enrollment for the ALPHA3 trial.
• File an IND application for ALLO-329 in Q1 2025.
• Provide a Phase 1 data update for ALLO-316 by the end of 2024.
• Continue enrollment in the Phase 1 ALPHA2 trial of cema-cel in CLL.
• Monitor the progress of the ALPHA3 trial and prepare for potential BLA submission in 2027.

Key Dates

Keywords

CAR T, Allogeneic, Cema-cel, Lymphoma, Autoimmune Disease, Renal Cell Carcinoma, Clinical Trial, Biotechnology, ALPHA3, ALLO-329, ALLO-316, Financial Results